Director of the Division of Molecular Pathology
Director of the Pathology Resource Network
Department of Pathology and Laboratory Medicine
Roswell Park Cancer Institutute

Carl D. Morrison, MD, DVM, has been appointed Director of the Division of Molecular Pathology in the Department of Pathology and Laboratory Medicine at Roswell Park Cancer Institute (RPCI).

Dr. Morrison will direct translational research efforts and the shared research resources in the department using sophisticated tests for the detection and diagnosis of cancer and innovative procedures for providing tumor samples to investigators for research.         

Dr. Morrison comes to RPCI from Ohio State University (OSU) where he most recently served as Assistant Professor of Pathology, Director of Pathology Core Facility, and Principal Investigator for the Cooperative Human Tissue Network.

At Roswell Park, Dr. Morrison will direct the Pathology Resource Network, which includes the Tissue Procurement Service, Paraffin Archive and Pathology Core Facility. Dr. Morrison will continue to pursue his research into cancer specimens using in-situ hybridization and tissue microarray, as well as his leadership on a national basis as part of the College of American Pathologists Molecular Pathology Committee.      

Dr. Morrison earned his doctor of veterinary medicine from Ohio State in 1982 and a medical degree from the University of Kentucky in 1998. He completed his residency training in Anatomic Pathology in 2001 and fellowships in Cytology in 2002 at the OSU Medical Center where he continued as a faculty member until coming to RPCI. He earned board certification in Veterinary Medicine and Anatomic Pathology. 

Dr. Morrison is a member of the American College of Pathology, United States and Canadian Academy of Pathology, and the American Society of Investigative Pathology. He has authored or co-authored more than 60 journal articles, abstracts and book chapters.

Selected Publications  (please click here for a PubMed list of Dr. Morrison's publications)

• Qin HR, Iliopoulos D, Semba S, Fabbri M, Druck T, Volinia S, Croce CM, Morrison CD, Klein RD, Huebner K. A Role for the WWOX Gene in prostate cancer. Cancer Res. 2006; 66:6477-6481
• Smith LT, Lin M, Brena RM, Lang JC, Schuller DE, Otterson GA, Morrison CD, Smiraglia DJ, Plass C. Epigenetic regulation of the tumor suppressor gene TCF21 on 6q23-q24 in lung and head and neck cancer. Proc Natl Acad Sci U S A. 2006; 103(4):982-987
• Tada Y, Brena RM, Hackanson B, Morrison C, Otterson GA, Plass C. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer. J Natl Cancer Inst. 2006; 98:396-406
• Joshi AS, Sharangpani GM, Porter K, Keyhani S, Morrison C, Basu AS, Gholap GA, Gholap AS, Barsky SH. Semi-automated imaging system to quantitate Her-2/neu membrane receptor immunoreactivity in human breast cancer. Cytometry A. 2007 Feb 23; [Epub ahead of print]
• Brena RM, Morrison C, Liyanarachchi S, Jarjoura D, Davuluri RV, Otterson GA, Reisman D, Glaros S, Rush LJ, Plass C. Aberrant DNA methylation of OLIG1, a novel prognostic factor in non-small cell lung cancer. PLoS Med. 2007 Mar 27;4(3):e108 [Epub ahead of print]